Clinical trials in Modena – page 4

387 clinical trials in Modena, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Modena at a glance

387

clinical trials

Research sites2

Quick filters

387 trials in Modena

Open in trial search

Non-small cell lung cancer

Recruiting

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Hormone-dependent prostate cancer

Recruiting

Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

Registered drugNo placebo

Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Apalutamide

Contact Research Centre

Coagulation factor X level

Recruiting

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:VMX-C001
Sponsor:VarmX B.V.

Contact Research Centre

Dyslipidaemia

Recruiting

Comparison of Obicetrapib and Bempedoic Acid in Patients with Dyslipidemia at High to Very High Cardiovascular Risk

Registered drug

Comparison of Obicetrapib and Bempedoic Acid in Patients with Dyslipidemia at High to Very High Cardiovascular Risk

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Bempedoic Acid

Contact Research Centre

Fallopian tube cancer+2

Recruiting

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Eli Lilly & Co.

Contact Research Centre

IgA nephropathy

Recruiting

Long-Term Safety Study of Zigakibart in Adults with IgA Nephropathy Who Have Completed Previous Zigakibart Trials

InvestigationalNo placebo

Long-Term Safety Study of Zigakibart in Adults with IgA Nephropathy Who Have Completed Previous Zigakibart Trials

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Zigakibart
Sponsor:Novartis Pharma AG

Contact Research Centre

A study to assess the safety of anumigilimab in adults with sickle cell disease

Recruiting

Investigational

A study to assess the safety of anumigilimab in adults with sickle cell disease

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Anumigilimab
Sponsor:CSL Behring LLC

Contact Research Centre

Ovarian cancer

Recruiting

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Registered drugNo placebo

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Idiopathic pulmonary fibrosis

Recruiting

Study to evaluate the safety and effectiveness of inhaled nintedanib in patients with idiopathic pulmonary fibrosis

Investigational

Study to evaluate the safety and effectiveness of inhaled nintedanib in patients with idiopathic pulmonary fibrosis

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Nintedanib
Sponsor:Avalyn Pharma Inc.

Contact Research Centre

Idiopathic pulmonary fibrosis

Recruiting

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:HUMANISED IGG1 LALAPS-YTE MONOCLONAL ANTIBODY AGAINST LYSOPHOSPHATIDIC ACID RECEPTOR 1
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Prophylaxis of nausea and vomiting+1

Recruiting

A Study to Evaluate LY3537021 and a Drug Combination for Treating Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Registered drug

A Study to Evaluate LY3537021 and a Drug Combination for Treating Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Registered drug

Italy

Participants:18–64 years
Substances:Aprepitant
Sponsor:Eli Lilly & Co.

Contact Research Centre

Clostridium difficile infection

Recruiting

A study to evaluate the effectiveness of AZD5148 in preventing the recurrence of Clostridioides difficile infection in adults.

Investigational

A study to evaluate the effectiveness of AZD5148 in preventing the recurrence of Clostridioides difficile infection in adults.

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:AZD5148
Sponsor:AstraZeneca AB

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Modena

What the registry says about research in the country

01 Respiratory Medicine

Innovative clinical trials exploring treatments for pulmonary fibrosis and severe asthma, evaluating novel therapies aimed at improving lung function and patient outcomes.

Idiopathic Pulmonary Fibrosis
Progressive Pulmonary Fibrosis
High-Risk Asthma

Research focuses on evaluating forced vital capacity changes and reducing asthma exacerbations.

02 Autoimmune Conditions

Groundbreaking studies examining treatments for systemic sclerosis and related autoimmune disorders, with emphasis on innovative biological therapies.

Diffuse Cutaneous Systemic Sclerosis
Systemic Autoimmune Rheumatic Diseases
Interstitial Lung Diseases

Studies aim to improve skin sclerosis and manage associated complications.

03 Oncology Research

Advanced trials investigating treatments for various cancers, including gastric cancer and hematological malignancies.

HER2-positive Gastric Cancer
Follicular Lymphoma
Metastatic Renal Cell Carcinoma

Focus on immunotherapy combinations and targeted treatments for better patient outcomes.

Back to Italy All countries